Pfizer obtained conditional approval from the European Commission to market Bosulif, or bosutinib, for adults with chronic phase, accelerated phase and blast phase Philadelphia chromosome positive chronic myelogenous leukemia previously treated with one or more tyrosine kinase inhibitors, who can't take imatinib, nilotinib and dasatinib. The approval was based on positive data from a Phase I/II trial involving more than 500 Ph+CML patients.
Pfizer's leukemia drug Bosulif wins conditional EU approval
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||